データなし
データなし
H.C. Wainwrightはアトサ・セラピューティクス(ATOS.US)のレーティングを強気に据え置き、目標株価を7ドルに据え置いた
H.C. WainwrightのアナリストEmily Bodnarは$Atossa Therapeutics(ATOS.US)$のレーティングを強気に据え置き、目標株価を7ドルに据え置いた。TipRanksのデータによると、このアナリストの最近1年間の的中率は30.0%、平均リターンは8.2%である。注 TipRanksは、金融アナリストの分析データと、アナリストの的中率および平均リターンに関する
HC Wainwright & Co. Reiterates Buy on Atossa Therapeuticsto Buy
Atossa Therapeutics To Present Data Describing the Discovery of Compounds That May Be Synergistic With (Z)-Endoxifen And That Could Potentially Be Used in Combinations For The Treatment Of Breast Cancer. The Data Will Be Presented In A Poster At The...
Atossa Therapeutics Announces Full Results From Phase 2 KARISMA-Endoxifen Study To Be Presented At 2024 San Antonio Breast Cancer Symposium; Demonstrated Statistically Significant Reductions In Mammographic Breast Density
Atossa Therapeutics Announces Full Results From Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data From Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium